Credits Available: 4.75 AMA PRA Category 1 Credit™/ MOC Points

Description: This curriculum examines the latest advancements in antibody-drug conjugate (ADC) therapy for metastatic triple-negative breast cancer (mTNBC) and HER2-low (HR+/HER2-) breast cancer. It provides insights into mechanisms of action, emerging clinical data, and strategies for integrating ADCs into treatment regimens to improve patient outcomes. Expert-led discussions and case-based learning will support clinicians in individualizing therapy and addressing real-world challenges in ADC use.

CME/CE Accreditation Information

If you already have a Gather-ed account, please login

Email:
Password:

Register

Step 1 of 3

This program is intended for:
Target Professions: DO, MD, Nurse Practitioner, Physician Associate/Assistant, Nurse, Pharmacist, Respiratory Therapist
Target Specialties: Oncology, Hematology/Oncology

Salamata Yoda

Bronxcare health System
FNP-Bc, PhD

Hi everyone, I’m Salamata Yoda, a Family Nurse Practitioner and an adjunct professor at Hostos Community College in New York. I have over 15 years of experience in nursing, and I specialize in women’s health, with a focus on breast cancer prevention. I’m also passionate about mentoring future nurses and serving underserved communities. I’m always open to connecting, learning from others, and collaborating on projects that improve patient outcomes and support the growth of our profession.